When GLP-1 receptor agonists — the class of drugs that includes semaglutide (Ozempic, Wegovy), liraglutide, and tirzepatide (Mounjaro, Zepbound) — began their meteoric rise, the assumption seemed logical: people losing weight would move more. Lighter bodies mean joints under less load, exercise feels easier, energy improves. The story wrote itself. Weight loss enables activity, activity reinforces weight loss, the cycle compounds toward health.

The data presented at ENDO 2026 — the Endocrine Society's annual meeting — tells a different story, and the implications for anyone using these drugs, training alongside them, or working in the fitness industry are significant enough to warrant a close reading.

The ENDO 2026 Study

Researchers from HSHS St. John's Hospital analyzed data from 753 participants in the National Institutes of Health's All of Us Research Program — a large-scale initiative that combines electronic health records with connected wearable data from devices including Fitbit. These were adults with obesity who had been prescribed a GLP-1 medication (semaglutide, liraglutide, dulaglutide, or tirzepatide) and had Fitbit activity data available both before and after their prescription.

The findings were the opposite of what the researchers anticipated. Following GLP-1 initiation, mean daily step count dropped from 5,047 to 4,487 steps per day — a decrease of 560 steps per day (p < 0.001). Moderate-to-vigorous physical activity (MVPA) fell from 27.9 minutes per day to 22.2 minutes per day — a reduction of 5.7 minutes per day (p < 0.001). These are statistically significant, objective, wearable-measured declines — not self-reported data, not survey estimates.

Study lead Dr. Sajana Maharjan was direct about the clinical implication: "Exercise cannot be optional for people taking these" medications. The study was not peer-reviewed at the time of conference presentation, and its retrospective design without a non-GLP-1 comparator group are legitimate methodological limitations. But the consistency of the finding — across drug types, across demographic subgroups — makes it difficult to dismiss as noise.

The declines were not evenly distributed. Men showed steeper activity reductions than women. Participants reporting musculoskeletal pain showed significantly larger drops. Age, heart failure history, and prior stroke did not significantly modify the pattern. The study population was 78.6% female with a mean age of 52.7 years.

Why This Is Happening

GLP-1 drugs work primarily through appetite suppression and slowing gastric emptying — reducing caloric intake and creating a sustained feeling of satiety. The drugs also act on the brain's reward pathways associated with food, which is part of why they produce weight loss that many users describe as qualitatively different from dieting: reduced food noise, fewer cravings, a fundamentally altered relationship with hunger.

The same central nervous system pathways that regulate appetite also regulate motivation and energy expenditure. This is not a new observation — research on other appetite-suppressing interventions has long noted that reduction in caloric intake tends to be accompanied by reduction in spontaneous physical activity. The body, sensing an energy deficit, attempts to reduce expenditure on both sides of the equation simultaneously. GLP-1 drugs may be triggering a similar compensatory mechanism at a neurobiological level, reducing the drive toward movement even as they reduce the drive toward food.

There is also a more prosaic explanation that likely contributes. GLP-1 drugs cause nausea, fatigue, and gastrointestinal discomfort — particularly in the early weeks of treatment and during dose escalation. These side effects make vigorous exercise genuinely unappealing, and if habits established during this period persist, the activity decline can become durable rather than temporary. Research on musculoskeletal pain as a moderator suggests that for those whose mobility was already limited by joint pain associated with obesity, the drugs may not yet have produced enough weight loss to meaningfully ease that pain while the side effects actively suppress motivation.

The Muscle Loss Problem

The activity decline matters acutely because of how GLP-1 drugs affect body composition. These medications produce weight loss through a combination of fat mass reduction and lean mass reduction. Multiple studies have documented that a meaningful proportion — in some analyses, 25–40% — of the total weight lost on GLP-1 drugs is lean mass, including skeletal muscle. This is consistent with what happens during any significant caloric restriction: the body breaks down both fat and protein-containing tissue to meet energy demands, and without a strong anabolic stimulus (resistance training, sufficient protein intake), lean mass is disproportionately sacrificed.

Muscle loss is not merely an aesthetic concern. Skeletal muscle is metabolically active tissue — it drives resting metabolic rate, improves insulin sensitivity, supports joint stability, and is the structural system that sustains functional independence across the lifespan. Reducing lean mass while reducing body weight results in a lower body fat percentage mathematically but leaves the body with a weaker metabolic engine, increased fragility, and a higher risk of weight regain when the drug is discontinued.

The ENDO 2026 finding creates a compounding problem: GLP-1 drugs already reduce lean mass alongside fat mass, and the activity decline they apparently induce removes the primary countermeasure — resistance training and general movement — that would otherwise preserve muscle through the weight loss period. The people who need exercise most, during GLP-1 treatment, are moving least.

Stanford's Muscle Regeneration Research

In June 2026, researchers at Stanford Medicine published findings on a potential pharmacological intervention to address GLP-1-related muscle loss. The research investigated whether an existing drug — already in clinical trials for age-related muscle loss (sarcopenia) — could preserve muscle regeneration in mice receiving GLP-1 medications. Young adult mice given the drug alongside a GLP-1 showed improved muscle regeneration and recovery compared to those receiving the GLP-1 alone.

The research is at an early stage — mouse models do not always translate directly to human outcomes — but the Stanford findings are notable because they suggest the muscle loss mechanism is biological and addressable, not merely a side effect of caloric restriction. The drug in question targets muscle satellite cells (the stem cells responsible for muscle repair), which appear to be functionally impaired by GLP-1 treatment in ways that go beyond simple caloric deficit.

What this means practically: the muscle preservation challenge during GLP-1 treatment may require more than just "lift weights and eat protein," though both remain the most evidence-based interventions currently available. Pharmacological solutions are on the research horizon, but they are not yet in clinical practice.

What the Numbers Look Like

Metric	Before GLP-1	After GLP-1	Change
Daily steps (mean)	5,047	4,487	−560 (−11%)
MVPA minutes/day	27.9	22.2	−5.7 min (−20%)
Lean mass loss (% of total weight lost)	—	25–40%	Significant
Weekly resistance training recommended	0 baseline	≥2 sessions	Prescription gap
Protein intake recommended (per kg LBM)	Standard 0.8g/kg	1.6–2.2g/kg	Doubled target

Sources: ENDO 2026 Fitbit study (Maharjan et al.); GLP-1 muscle loss literature review (U.S. News Health); Stanford Medicine June 2026 research.

The Fitness Industry's Quiet Inflection Point

The GLP-1 market is large and growing rapidly. As of 2026, tens of millions of people globally are taking these medications. This is not a niche population that trainers and fitness apps can treat as an edge case. GLP-1 users are now a mainstream segment of the fitness market — and they have a specific, research-documented need that most current fitness programming is not designed to address.

Traditional fitness programming assumes a baseline of motivation, caloric intake sufficient to support training, and a body composition trajectory driven by exercise rather than pharmacology. GLP-1 users present a different profile: reduced appetite and caloric intake (often too low to support resistance training recovery), drug-induced fatigue and nausea (particularly early in treatment), a strong weight loss trajectory that may not be matched by body composition improvements, and — as the ENDO 2026 study shows — reduced spontaneous physical activity.

What this population needs from a fitness intervention is specific: resistance-first programming (to protect lean mass), moderate volume with careful attention to recovery (given reduced caloric availability), protein targets substantially above the standard 0.8g/kg bodyweight recommendation (evidence supports 1.6–2.2g/kg of lean body mass for muscle preservation during caloric restriction), and structured accountability that sustains activity levels the drug may be subtly suppressing.

This is not a trivial ask. It requires a training program designed around the pharmacological context, not designed generically and then handed to a GLP-1 user. It requires nutrition guidance that accounts for the drug's effect on appetite and the elevated protein requirements of the situation. And it requires monitoring — tracking not just weight loss (the metric the drugs produce by default) but lean mass preservation, training frequency, and daily activity levels.

What to Do if You Are on a GLP-1

The research converges on a practical protocol that should be treated as standard of care for GLP-1 users rather than an optional add-on.

Start resistance training immediately. Do not wait until you have lost weight, feel better, or the nausea subsides. Even two resistance sessions per week — bodyweight exercises, machine-based work, or barbell training — provide a meaningful anabolic stimulus that reduces the proportion of lean mass lost during the weight loss period. The earlier this habit is established, the more lean mass is preserved across the full treatment duration.

Prioritize protein intake. Appetite suppression is one of the drug's primary mechanisms, which means users are often eating less protein than their body needs to maintain lean mass through weight loss. Target at least 1.6 grams of protein per kilogram of lean body mass — and ideally 1.8–2.2g/kg if resistance training is inconsistent or caloric intake is very low. Prioritize high-quality complete protein sources: animal proteins (eggs, chicken, Greek yogurt, cottage cheese, fish) or well-planned plant combinations. Protein timing matters less than total daily intake, but consuming a substantial serving (30–40g) at each meal makes hitting targets easier when appetite is suppressed.

Track your steps and movement. The ENDO 2026 data shows that the activity decline is real and likely goes unnoticed by users who feel they are "doing well" because the scale is moving. A wearable that tracks daily steps and active minutes provides objective feedback that compensates for the reduced interoceptive drive toward movement. If your step count is falling week-over-week, that is a signal requiring deliberate intervention — not a comfortable adaptation to accept.

Structure your activity. Unstructured "be more active" advice produces modest results in any population; it produces even less reliable results in a population experiencing appetite and motivation suppression. Scheduled, calendar-blocked training sessions — with the specificity of what you will do, when, and for how long — outperform intention in every behavior research context. Accountability partnerships and community environments have measurable effects on exercise adherence, particularly during periods when intrinsic motivation is reduced.

Monitor composition, not just weight. The scale number is a poor guide to the success of your GLP-1 treatment from a health and fitness perspective. Body weight loss that is 35% lean mass and 65% fat has a very different outcome trajectory than loss that is 90% fat and 10% lean mass. Periodic DEXA scans, InBody measurements, or consistent grip strength and functional fitness testing provide data that pure scale-watching cannot.

A Note on the Fitness App Opportunity

The GLP-1 population represents a specific, underserved gap in the fitness technology market. Most fitness apps are built around the assumption that the challenge is motivation and programming — not pharmacological suppression of spontaneous activity combined with elevated lean mass preservation requirements. An app experience designed for GLP-1 users would prioritize resistance training above cardio, set aggressive protein targets, surface daily step count as a primary metric alongside workout completion, and provide the social accountability layer that compensates for chemically blunted motivation.

ROID's AI fitness platform tracks health metrics alongside training data, providing the integrated picture that GLP-1 users specifically need — not just whether you completed a workout, but how your overall activity, nutrition, and recovery are trending week over week. The nutrition tracking layer supports the high-protein targets that are non-negotiable for lean mass preservation during GLP-1 treatment.

The research is clear: GLP-1 drugs produce weight loss. They do not automatically produce the body composition, metabolic health, or functional fitness outcomes that make that weight loss durable and beneficial long-term. Exercise — structured, progressive, resistance-prioritized — is the mechanism that converts pharmacological weight loss into health. The ENDO 2026 data shows that without deliberate intervention, the drugs may actually be working against the exercise habit they should be reinforcing. That is the gap worth closing.